X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (418) 418
index medicus (314) 314
male (265) 265
animals (253) 253
uridine monophosphate - analogs & derivatives (242) 242
female (202) 202
sofosbuvir (186) 186
hepatitis c, chronic - drug therapy (164) 164
uridine monophosphate - therapeutic use (163) 163
antiviral agents - therapeutic use (150) 150
middle aged (133) 133
pharmacology & pharmacy (124) 124
rats (119) 119
hepatitis c (118) 118
uridine (114) 114
uridine monophosphate - administration & dosage (114) 114
hepacivirus - genetics (106) 106
treatment outcome (105) 105
drug therapy, combination (99) 99
antiviral agents - administration & dosage (98) 98
ribavirin (97) 97
genotype (95) 95
hepatitis c virus (95) 95
adult (93) 93
gastroenterology & hepatology (92) 92
mice (82) 82
aged (80) 80
hepatitis (74) 74
ribavirin - therapeutic use (74) 74
uridine - metabolism (73) 73
benzimidazoles - therapeutic use (70) 70
fluorenes - therapeutic use (70) 70
antiviral agents - adverse effects (68) 68
hepatitis c - drug therapy (68) 68
uridine monophosphate - adverse effects (65) 65
hepacivirus - drug effects (62) 62
interferon (59) 59
benzimidazoles - administration & dosage (58) 58
drug therapy (58) 58
fluorenes - administration & dosage (58) 58
biochemistry & molecular biology (56) 56
time factors (56) 56
therapy (55) 55
ledipasvir (54) 54
analysis (53) 53
liver (52) 52
abridged index medicus (51) 51
antiviral agents (51) 51
nucleotides (51) 51
care and treatment (50) 50
hepatitis c, chronic - virology (50) 50
metabolism (50) 50
infection (49) 49
ribavirin - administration & dosage (48) 48
cirrhosis (47) 47
hcv (47) 47
uridine - pharmacology (46) 46
kinetics (43) 43
administration, oral (42) 42
medicine, general & internal (42) 42
health aspects (41) 41
dose-response relationship, drug (40) 40
oncology (40) 40
virus-infection (40) 40
liver - metabolism (39) 39
5-fluorouracil (38) 38
nucleosides (38) 38
research (37) 37
genotype & phenotype (36) 36
infections (36) 36
neurosciences (36) 36
uridine - analogs & derivatives (36) 36
genotype 1 infection (35) 35
simeprevir (35) 35
sustained virologic response (35) 35
treatment-naive patients (35) 35
uridine monophosphate - pharmacology (35) 35
drug combinations (34) 34
benzimidazoles - adverse effects (33) 33
enzymes (33) 33
fluorenes - adverse effects (33) 33
rna - biosynthesis (33) 33
gastroenterology and hepatology (32) 32
patients (32) 32
united states (32) 32
drug administration schedule (31) 31
internal medicine (31) 31
medicine (31) 31
biological response modifiers (30) 30
genetic aspects (30) 30
plus ribavirin (30) 30
cancer (29) 29
ribavirin - adverse effects (29) 29
sustained virological response (29) 29
liver cirrhosis - virology (28) 28
medicine & public health (28) 28
metabolites (28) 28
brain (27) 27
combination (27) 27
docosahexaenoic acid (27) 27
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 16, pp. 1483 - 1493
Journal Article
JAMA, ISSN 0098-7484, 08/2013, Volume 310, Issue 8, pp. 804 - 811
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 6, pp. 645 - 653
Summary Background Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older, have more advanced liver disease, and... 
Infectious Disease | INFECTIOUS DISEASES | SIMEPREVIR | INFECTION | CHRONIC HCV | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Benzimidazoles - administration & dosage | Time Factors | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Hepacivirus - isolation & purification | Administration, Oral | Japan | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Asian Continental Ancestry Group | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Liver | Dosage and administration | Product development | Drug therapy, Combination | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Liver cancer | Heart attacks | Liver diseases | Human immunodeficiency virus--HIV | Hepatology | Response rates | Interferon | Infections | Drug dosages | Patients
Journal Article
Journal Article
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 151, Issue 3, pp. 457 - 471.e5
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 151, Issue 6, pp. 1131 - 1140.e5
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9883, pp. 2100 - 2107
Journal Article
Journal Article